<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390295</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3824-302</org_study_id>
    <nct_id>NCT04390295</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Clinical Trial to Evaluate the Efficacy and Safety of SHR3824 Combined With Metformin in Metformin Monotherapy Poorly Glycemic Controlled Chinese Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain information on efficacy and safety of SHR3824 with
      metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled
      chinese Type 2 Diabetes. Efficacy and safety will be evaluated by comparing the effect of
      SHR3824 with metformin to placebo with metformin when given in oral doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase III clinical study on efficacy and safety of SHR3824 combined with metformin for type
      2 diabetes with poor glucose control in metformin monotherapy (multicenter, randomized,
      double-blind, placebo-parallel control). The 450 subjects received at least eight weeks of
      metformin monotherapy at a steady dose of 1500 mg or more before screening.

      Evaluation of efficacy: compared with the group of placebo combined with metformin, HbA1c,
      fasting plasma glucose, postprandial plasma glucose, fasting body weight and blood pressure
      changes in the SHR3824 with metformin group
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in HbA1c Levels</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Compared with the placebo with metformin group, mean change in HbA1c Levels in SHR3824 with metformin group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Fasting Plasma Glucose</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Compared with the placebo with metformin group, mean change in Fasting Plasma Glucose Levels in SHR3824 with metformin group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measurement of safety</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Compared with the placebo with metformin group, the incidence of adverse events in SHR3824 with metformin group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SHR3824+Metformin, Placebo+Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR3824 5 mg+Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily for SHR3824, three times daily for metformin, 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR3824 10 mg+Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily for SHR3824, three times daily for metformin, 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, 24 weeks</description>
    <arm_group_label>SHR3824+Metformin, Placebo+Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3824</intervention_name>
    <description>Once daily, 52 weeks</description>
    <arm_group_label>SHR3824 10 mg+Metformin</arm_group_label>
    <arm_group_label>SHR3824 5 mg+Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Three times daily, 52 weeks</description>
    <arm_group_label>SHR3824 10 mg+Metformin</arm_group_label>
    <arm_group_label>SHR3824 5 mg+Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of type 2 diabetes mellitus;

          -  Patients with type 2 diabetes mellitus treated with metformin monotherapy for ≥ 8
             weeks and poor glycemic control, metformin dose stabilized ≥1500mg / day;

          -  FPG&lt;=15mmol/L;

          -  Hemoglobin A1c levels &gt;=7.0% and &lt;=10.5%;

          -  Body mass index (BMI) 19 to 35 kg/m2;

        Exclusion Criteria:

          -  Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or
             secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);

          -  Past or current history of severe diabetic complications (proliferative diabetic
             retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or
             serious diabetic neuropathy);

          -  Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the
             start or end day of the run-in period;

          -  History of myocardial infarction, unstable angina, or cerebrovascular disorder within
             6 months before the start of the run-in period;

          -  Past or current history of malignant tumor;

          -  Past or current history of drug hypersensitivity such as shock and anaphylactoid
             symptoms;

          -  Pregnant women, lactating mothers, or women of childbearing potential;

          -  Any condition that subjects are assessed to be ineligible by the investigator (sub
             investigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>WENG Jianping, professor</last_name>
    <phone>86-020-85250217</phone>
    <email>wjianp@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CHEN Jianwen, professor</last_name>
    <phone>18036611985</phone>
    <email>chenjianwen@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat - sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weng Jianping, professor</last_name>
      <phone>86-(20)85253239</phone>
      <email>wjianp@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chen Jianwen</last_name>
      <phone>18036611985</phone>
      <email>chenjianwen@hrglobe.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

